Media CoverageBack to Media Coverage
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
In patients who suffer from Type I diabetes, pancreatic beta cells are killed off by the immune system. Lilly and Sigilon plan to encapsulate induced pluripotent stem cells that are engineered into insulin-producing pancreatic beta cells. Ultimately, the companies hope, these products can restore a person’s insulin production without alarming their immune system.